IL6 and diabetes mellitus: A study by Luo et al. [10] provide in vivo evidence that KMP reduced inflammatory lesion in diabetes by reducing TNF-α and IL-6 levels along with the downregulation of IKK and subsequent inhibition of NF-κB pathway activation.